基于国家专利中药复方治疗过敏性鼻炎用药规律与机制研究

Research on Medication Rules and Mechanism for Treatment of Allergic Rhinitis Based on National Patents TCM Compound

目的通过对治疗过敏性鼻炎国家专利中药复方的挖掘,获取其用药规律,为中药新药研发提供依据。方法检索获取国家知识产权局专利库中治疗过敏性鼻炎的中药复方专利数据,将数据录入中医传承辅助平台(V2.5)并统计药物频次,分析关联规则,构建复杂网络,获取核心药物,筛选关键药物并用中药网络药理学的方法探索关键药物的潜在作用机制。结果纳入中药复方专利数据220条,共涉及中药614味,主要证候为肺虚感寒证与肺经伏热证;最常用的药物为防风(108次,49.1%)、辛夷(106次,48.2%)、白芷(98次,44.6%)等;最常用的对药为防风-辛夷;最常用的角药为黄芪-防风-辛夷、白芷-防风-辛夷等;高置信度药物关联规则有白术-防风-辛夷->黄芪、黄芪-白术-辛夷->防风等;核心药物包括为防风、辛夷、白芷、苍耳子、黄芪;关键药物为防风、辛夷、白芷。获取了关键药物的活性成分汉黄芩素、谷甾醇、亚油酸乙酯等,获得了上述活性成分与过敏性鼻炎的交集靶点ESR1、AR、BCL2、IL-6、ADRA2C等,富集分析得到交集靶点的KEGG富集通路49条如PI3K/Akt信号通路、Calcium信号通路、HIF-1信号通路、NF-kappa B信号通路、MAPK信号通路等,在此基础上构建了关键药物-成分-靶点-通路网络。结论关键药物对过敏性鼻炎的治疗存在分子层面的作用机制为依据,治疗过敏性鼻炎的中药新药研发可依据获取的用药规律,灵活运用温肺散寒、益气固表与清热祛风、益气止嚏之法,并辅以补脾益肺、温阳益气,从而提高临床疗效。

Objective Through the mining of the national patented traditional Chinese medicine compound for the treatment of allergic rhinitis,the laws of drug use are obtained,which provide a basis for the research and development of new Chinese medicines.Methods Search and obtain the patent data of traditional Chinese medicine compound for treating allergic rhinitis in the patent library of the State Intellectual Property Office,enter data into the TCM Inheritance Support System(V2.5)and count the frequency of drugs,analyze association rules,build complex networks,acquire core drugs,screen key drugs and explore the potential mechanism of action of key drugs by using traditional Chinese medicine network pharmacology.Results 220 compound TCM patents in total were included,and 614 kinds of Chinese materia medica were involved.The most common syndromes were lung-deficiency-related cold syndrome and latent heat in the lung meridian syndrome.The most common Chinese materia medica were Saposhnikovia divaricata(108 times,accounting for 49.09%),Flos Magnoliae(106 times,accounting for 48.18%),and Angelica dahurica(98 times,accounting for 44.55%).The most common medical combination was"Saposhnikovia divaricate-Flos Magnoliae".The most common triple combinations were"Radix AstragaliSaposhnikovia divaricate-Flos Magnoliae""Angelica dahurica-Saposhnikovia divaricate-Flos Magnoliae"etc.Confidence-based association rules were"Bighead Atractylodes Rhizome-Saposhnikovia divaricateFlos Magnoliae->Radix Astragali""Radix Astragali-Bighead Atractylodes Rhizome-Flos Magnoliae->Saposhnikovia divaricate"etc.The core medicines were Saposhnikovia divaricate,Flos Magnoliae,Angelica dahurica,etc.The key drugs were Saposhnikovia divaricate,Flos Magnoliae,and Angelica dahurica.The active components obtained from the key drugs were wogonin,sitosterol,mandenol,etc.The intersection targets of the above active components and allergic rhinitis were obtained,such as ESR1,AR,BCL2,IL-6,ADRA2 C,etc.The results of enrichment analysis showed that there were 49 enrichment pathways of KEGG,such as PI3 K/Akt signaling pathway,Calcium signaling pathway,NF-kappa B signaling pathway,MAPK signaling pathway,etc.On this basis,the key medicines-components-target-pathway network was constructed.Conclusion The therapeutic effect of key medicines on allergic rhinitis is based on the molecular mechanism,the research and development of new traditional Chinese medicine for allergic rhinitis can be based on the acquired medication rules,the methods of warming the lung,dispersing cold,supplementing Qi and strengthening the surface,clearing away heat and wind,supplementing Qi and stopping sneezing should be used flexibly,in addition,it is supplemented by tonifying the spleen and lung,warming Yang and Qi,so as to improve the clinical effect.